A Rapid Approach To Streamlined CART Therapies And Reduced Cost Of Goods

By Matthew Cash, Richard Smindak, Stefan Herrera, Devin Stranford, Hailey Edelstein, Mahdy Al Majed Yassine, Joshua Leonard, Matteo Stoppato, Roger Herr, and Bruce Thompson

Reducing cost of goods (COGs) and increasing batch success are critical to expanding access to transformative cell therapies. Novel engineering vector technology addresses these challenges by selectively targeting and activating specific cell types while efficiently mediating transduction. This single-step approach completely eliminates the need for external activation reagents and cell isolation steps traditionally required in CAR-T cell manufacturing.

Integrating this engineered vector into existing manufacturing workflows reduces processing time by approximately 40% and delivers an estimated 55% reduction in COGs. These significant labor and material savings are achieved alongside robust cell growth, high CAR expression, and high T-cell purity. Ultimately, this streamlined methodology scales production and maintains industry-aligned product potency.

Review the complete technical data to explore these optimized process development strategies in detail.